(Enhancing Effect Of CpG-ODNs On Mice Melanoma In Magnetic Fluid Hyperthermia)

Objective:In tumor-bearing mice model, study the effect of CpG-ODNs for melanoma with magnetic fluid hyperthermia, and explore the possible immune enhancement mechanism, so as to provide the experimental basis for the optimization of magnetic fluid hyperthermia therapy.Methods:1Establish the bilateral tumor-bearing mouse model. The magnetic fluid hyperthermia is applied on one side of the transplanted tumor, combined with CpG-ODNs adjuvant immunotherapy. The mice were divided into four groups:group a:control group; b. simple CpG-ODNs injection group; c. simple hyperthermia group; d. combined treatment of with CpG-ODNs;2Record the survival time of mice, observe the extinction of bilateral tumors, evaluation of combined treatment in situ and ectopic effect on tumor-bearing host. To evaluate various treatment curative effect on tumor-bearing mice;3.Detect of serum Thl type cytokines IL-2, IL-12, TNF-α and Th2type cytokines IL-4after treatment, and the secretion level of Thl type cytokines IL-2, TNF-α in the spleen supernatants, to evaluate the transfer function of Th1/Th2and the Thl and Th2cell immune response;4. Detect the ratio of spleen Treg cell subsets in the T lymphocyte, to explore the relationship between the effect of the combined treatment of Treg cells.Results:1. Mice in combined treatment group have a longer survival time and a more obvious regression of tumor treatment side effects and ectopic compared with the other three groups (p<0.05);2. The serum Thl cytokines IL-2, IL-12, TNF-α of the combined treatment group are significantly increased than the other three groups while Th2type cytokine IL-4decreased significantly (p<0.05);3. The Th1type cytokines in spleen cells of the combined treatment group are also significantly increased than the other three groups;4. The ratio of spleen Treg cell subsets in four groups have no significant differences (p>0.05).Conclusion:Magnetic fluid hyperthermia combined with a novel adjuvant CpG-ODNs in the treatment of melanoma in mice can improve the therapeutic effect by prolong survival time, improve the situ and ectopic effect. The possible Immune enhancement effect is improving the Th1cell response immune system by releasing cytokines IL-2, TNF-α, IL-12, and inhibition of cytokine release of IL-4, so as to increase antitumor immune response.